Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer

Franco Lumachi, Mario Ermani, Filippo Marino, Loretta Di Cristofaro, Valeria Tombolan, Antonella Brunello, Anna Roma, Umberto Basso

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Breast cancer (BC) is the most common cancer in women, and the hormone receptor status is one of the most important prognostic factors in patients with BC. The aim of this study was to establish whether a relationship exists between the hormone receptor rate and the main classic risk factors in patients with BC. Patients and Methods: The data regarding a series of 351 consecutive women (median age 57 years, range 26-85 years) who had undergone curative surgery for primary BC was retrospectively reviewed. Eighty-seven (24.8%) patients used oral contraceptives. According to the duration of OC therapy, the patients were dichotomized into two Groups. Group A: less than 22 months (47 patients, 54%) and Group B: 22 months or more (40 patients, 46%). Results: Final pathology showed 15 (4.3%) pT1a, 62 (17.7%) pT1b, 133 (37.9%) pT1c, 125 (35.6%) pT2, and 16 (4.5%) pT3 BC. There were 286 (81.5%) infiltrating ductal, and 24 (6.8%) infiltrating lobular breast carcinomas. The average estrogen receptor (ER) and progesterone receptor (PgR) rate was 59.7±32.8 and 54.2±33.9, respectively. There was no relationship (p=NS) between either ER or PgR and the age of the patients, age at menarche and menopause, number of pregnancies, age at first pregnancy, number of spontaneous abortions, months of breastfeeding and the use of estrogen replacement therapy. As expected, ER and PgR rates correlated significantly (R=0.78, p

Original languageEnglish
Pages (from-to)491-493
Number of pages3
JournalAnticancer Research
Volume28
Issue number1 B
Publication statusPublished - Jan 2008

Fingerprint

Oral Contraceptives
Estrogen Receptors
Breast Neoplasms
Progesterone Receptors
Therapeutics
Hormones
Lobular Carcinoma
Pregnancy
Menarche
Estrogen Replacement Therapy
Spontaneous Abortion
Menopause
Breast Feeding
Pathology
Neoplasms

Keywords

  • Breast cancer
  • Estrogen receptor
  • Oral contraceptives
  • Progesterone receptor
  • Risk factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer. / Lumachi, Franco; Ermani, Mario; Marino, Filippo; Di Cristofaro, Loretta; Tombolan, Valeria; Brunello, Antonella; Roma, Anna; Basso, Umberto.

In: Anticancer Research, Vol. 28, No. 1 B, 01.2008, p. 491-493.

Research output: Contribution to journalArticle

Lumachi, F, Ermani, M, Marino, F, Di Cristofaro, L, Tombolan, V, Brunello, A, Roma, A & Basso, U 2008, 'Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer', Anticancer Research, vol. 28, no. 1 B, pp. 491-493.
Lumachi F, Ermani M, Marino F, Di Cristofaro L, Tombolan V, Brunello A et al. Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer. Anticancer Research. 2008 Jan;28(1 B):491-493.
Lumachi, Franco ; Ermani, Mario ; Marino, Filippo ; Di Cristofaro, Loretta ; Tombolan, Valeria ; Brunello, Antonella ; Roma, Anna ; Basso, Umberto. / Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer. In: Anticancer Research. 2008 ; Vol. 28, No. 1 B. pp. 491-493.
@article{101ea232bf334d5b965a3381f782e15e,
title = "Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer",
abstract = "Background: Breast cancer (BC) is the most common cancer in women, and the hormone receptor status is one of the most important prognostic factors in patients with BC. The aim of this study was to establish whether a relationship exists between the hormone receptor rate and the main classic risk factors in patients with BC. Patients and Methods: The data regarding a series of 351 consecutive women (median age 57 years, range 26-85 years) who had undergone curative surgery for primary BC was retrospectively reviewed. Eighty-seven (24.8{\%}) patients used oral contraceptives. According to the duration of OC therapy, the patients were dichotomized into two Groups. Group A: less than 22 months (47 patients, 54{\%}) and Group B: 22 months or more (40 patients, 46{\%}). Results: Final pathology showed 15 (4.3{\%}) pT1a, 62 (17.7{\%}) pT1b, 133 (37.9{\%}) pT1c, 125 (35.6{\%}) pT2, and 16 (4.5{\%}) pT3 BC. There were 286 (81.5{\%}) infiltrating ductal, and 24 (6.8{\%}) infiltrating lobular breast carcinomas. The average estrogen receptor (ER) and progesterone receptor (PgR) rate was 59.7±32.8 and 54.2±33.9, respectively. There was no relationship (p=NS) between either ER or PgR and the age of the patients, age at menarche and menopause, number of pregnancies, age at first pregnancy, number of spontaneous abortions, months of breastfeeding and the use of estrogen replacement therapy. As expected, ER and PgR rates correlated significantly (R=0.78, p",
keywords = "Breast cancer, Estrogen receptor, Oral contraceptives, Progesterone receptor, Risk factors",
author = "Franco Lumachi and Mario Ermani and Filippo Marino and {Di Cristofaro}, Loretta and Valeria Tombolan and Antonella Brunello and Anna Roma and Umberto Basso",
year = "2008",
month = "1",
language = "English",
volume = "28",
pages = "491--493",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer

AU - Lumachi, Franco

AU - Ermani, Mario

AU - Marino, Filippo

AU - Di Cristofaro, Loretta

AU - Tombolan, Valeria

AU - Brunello, Antonella

AU - Roma, Anna

AU - Basso, Umberto

PY - 2008/1

Y1 - 2008/1

N2 - Background: Breast cancer (BC) is the most common cancer in women, and the hormone receptor status is one of the most important prognostic factors in patients with BC. The aim of this study was to establish whether a relationship exists between the hormone receptor rate and the main classic risk factors in patients with BC. Patients and Methods: The data regarding a series of 351 consecutive women (median age 57 years, range 26-85 years) who had undergone curative surgery for primary BC was retrospectively reviewed. Eighty-seven (24.8%) patients used oral contraceptives. According to the duration of OC therapy, the patients were dichotomized into two Groups. Group A: less than 22 months (47 patients, 54%) and Group B: 22 months or more (40 patients, 46%). Results: Final pathology showed 15 (4.3%) pT1a, 62 (17.7%) pT1b, 133 (37.9%) pT1c, 125 (35.6%) pT2, and 16 (4.5%) pT3 BC. There were 286 (81.5%) infiltrating ductal, and 24 (6.8%) infiltrating lobular breast carcinomas. The average estrogen receptor (ER) and progesterone receptor (PgR) rate was 59.7±32.8 and 54.2±33.9, respectively. There was no relationship (p=NS) between either ER or PgR and the age of the patients, age at menarche and menopause, number of pregnancies, age at first pregnancy, number of spontaneous abortions, months of breastfeeding and the use of estrogen replacement therapy. As expected, ER and PgR rates correlated significantly (R=0.78, p

AB - Background: Breast cancer (BC) is the most common cancer in women, and the hormone receptor status is one of the most important prognostic factors in patients with BC. The aim of this study was to establish whether a relationship exists between the hormone receptor rate and the main classic risk factors in patients with BC. Patients and Methods: The data regarding a series of 351 consecutive women (median age 57 years, range 26-85 years) who had undergone curative surgery for primary BC was retrospectively reviewed. Eighty-seven (24.8%) patients used oral contraceptives. According to the duration of OC therapy, the patients were dichotomized into two Groups. Group A: less than 22 months (47 patients, 54%) and Group B: 22 months or more (40 patients, 46%). Results: Final pathology showed 15 (4.3%) pT1a, 62 (17.7%) pT1b, 133 (37.9%) pT1c, 125 (35.6%) pT2, and 16 (4.5%) pT3 BC. There were 286 (81.5%) infiltrating ductal, and 24 (6.8%) infiltrating lobular breast carcinomas. The average estrogen receptor (ER) and progesterone receptor (PgR) rate was 59.7±32.8 and 54.2±33.9, respectively. There was no relationship (p=NS) between either ER or PgR and the age of the patients, age at menarche and menopause, number of pregnancies, age at first pregnancy, number of spontaneous abortions, months of breastfeeding and the use of estrogen replacement therapy. As expected, ER and PgR rates correlated significantly (R=0.78, p

KW - Breast cancer

KW - Estrogen receptor

KW - Oral contraceptives

KW - Progesterone receptor

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=40549144829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40549144829&partnerID=8YFLogxK

M3 - Article

C2 - 18383890

AN - SCOPUS:40549144829

VL - 28

SP - 491

EP - 493

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -